Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has provided an announcement.
Cinclus Pharma Holding AB has secured a structured credit facility of up to EUR 28 million from Claret Capital Partners to accelerate development of its lead acid-reflux treatment, linaprazan glurate, and support pre-launch activities ahead of potential market approval in the U.S. and Europe. The funding, divided into four milestone-based tranches and combining secured term loans with convertibles and warrants, allows an earlier start of the final Phase III program stage while keeping the first Phase III study fully financed and aims to minimize shareholder dilution as the company advances toward commercialization in a multi-billion-euro market.
The initial EUR 8 million tranche has already been drawn as a convertible with a set premium conversion price, and subsequent tranches are contingent on positive Phase III data and sizable equity raises, reflecting both confidence in the asset’s clinical profile and a structured risk-sharing approach between lender and company. Claret Capital views linaprazan glurate as a potential best-in-class therapy capable of redefining treatment standards for severe gastroesophageal reflux disease, and the deal strengthens Cinclus Pharma’s financial position at a pivotal late-stage development phase, with implications for its competitive standing and existing shareholders’ dilution profile.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing next-generation treatments for gastric acid-related diseases. Its lead product candidate, linaprazan glurate, is a potassium-competitive acid blocker targeting gastroesophageal reflux disease, a large global market with unmet needs, especially among patients not responding to standard therapies.
Average Trading Volume: 38,512
Technical Sentiment Signal: Sell
Current Market Cap: SEK794.9M
Find detailed analytics on CINPHA stock on TipRanks’ Stock Analysis page.